{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:50:21Z","timestamp":1793724621910,"version":"4.6.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,18]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To systematically analyze the value of human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) in the diagnosis of endometrial cancer, so as to provide evidence-based medical evidence for the selection of serum tumor markers in the early screening of endometrial cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We comprehensively searched relevant literature in the Cochrane Library, EMBASE, PubMed, Web of Science, CNKI, VIP, WanFang, and CBM from the date of establishment to November 31, 2021. Quality assessment of diagnostic accuracy studies 2 was applied to evaluate the quality of the included literature. We used Stata 16.0 to calculate the pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR) and plot summary receiver operating characteristic curve, as well as to assess diagnostic accuracy using the area under the curve (AUC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 25 studies, including 1980 patients and 2345 controls, were included in this meta-analysis. The pooled SEN, SPE, PLR, NLR, DOR, and AUC of HE4 were 0.58 (95% CI 0.52\u20130.63), 0.95 (95% CI 0.92\u20130.97), 11.57 (95% CI 6.88\u201319.48), 0.45 (95% CI 0.39\u20130.51), 25.92 (95% CI 14.84\u201345.26), and 0.80 (95% CI 0.76\u20130.83), respectively. The pooled SEN, SPE, PLR, NLR, DOR, and AUC of CA125 were 0.41 (95% CI 0.34\u20130.49), 0.91 (95% CI 0.85\u20130.95), 4.55 (95% CI 2.73\u20137.58), 0.65 (95% CI 0.57\u20130.74), 7.03 (95% CI 3.92\u201312.62), and 0.68 (95% CI 0.64\u20130.72), respectively. The pooled SEN, SPE, PLR, NLR, DOR, and AUC of HE4\u2005+\u2005CA125 were 0.67 (95% CI 0.60\u20130.73), 0.92 (95% CI 0.87\u20130.95), 8.59 (95% CI 5.32\u201313.86), 0.36 (95% CI 0.30\u20130.44), 23.80 (95% CI 13.86\u201340.86), and 0.85 (95% CI 0.82\u20130.88), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This Meta-analysis found that HE4 alone or in combination with CA125 showed better diagnostic efficacy than CA125, regardless of clinical stage and pathological type. HE4\u2005+\u2005CA125 had slightly higher diagnostic efficiency than HE4, but did not show significant advantages. While the studies were heterogeneous, the credibility of the findings needs to be further confirmed by more homogeneous, prospective, and large sample size studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000034737","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T13:02:35Z","timestamp":1692622955000},"page":"e34737","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Diagnostic value of serum human epididymis protein 4, carbohydrate antigen 125 and their combination in endometrial cancer: A meta-analysis"],"prefix":"10.1097","volume":"102","author":[{"given":"Qi","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hebei General Hospital, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-ning","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hebei General Hospital, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-yun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hebei General Hospital, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-fei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hebei General Hospital, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3669-3027","authenticated-orcid":false,"given":"Li-na","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hebei General Hospital, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011.","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up.","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1056\/NEJMc2035378","article-title":"Endometrial cancer. Reply.","volume":"384","author":"Lu","year":"2021","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/AOG.0000000000002626","article-title":"ACOG committee opinion No. 734 summary: the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding.","volume":"131","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/1096-9098(200012)75:4<264::AID-JSO7>3.0.CO;2-Q","article-title":"Benign conditions associated with raised serum CA-125 concentration.","volume":"75","author":"Buamah","year":"2000","journal-title":"J Surg Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"781","DOI":"10.5603\/GP.2016.0088","article-title":"The role of HE4 and CA125 in differentiation between malignant and non-malignant endometrial pathologies.","volume":"87","author":"Abdalla","year":"2016","journal-title":"Ginekol Pol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erm.09.39","article-title":"HE4 as a biomarker for ovarian and endometrial cancer management.","volume":"9","author":"Li","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2020.12.029","article-title":"Endometrial cancer: a systematic review of HE4, REM and REM-B.","volume":"515","author":"Degez","year":"2021","journal-title":"Clin Chim Acta"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13277-012-0583-0","article-title":"The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.","volume":"34","author":"Angioli","year":"2013","journal-title":"Tumor Biol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/bjc.2011.109","article-title":"Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients.","volume":"104","author":"Bignotti","year":"2011","journal-title":"Brit J Cancer"},{"key":"R12-20250504","first-page":"1054","article-title":"Clinical value of combined detection of HE4, CA125 in application of endometrial carcinoma.","volume":"27","author":"Chen","year":"2016","journal-title":"Hainan Med J"},{"key":"R13-20250504","first-page":"905","article-title":"Clinical significance of serum CA125 and HE4 tests in endometrial cancer.","volume":"0","author":"Cui","year":"2019","journal-title":"Mod Digest Intervention"},{"key":"R14-20250504","first-page":"C1","article-title":"Diagnostic performance of serum human epididymis protein 4 in endometrial carcinoma: a pilot study.","volume":"11","author":"Dewan","year":"2017","journal-title":"J Clin Diagnostic Res"},{"key":"R15-20250504","first-page":"165","article-title":"Clinical value of human epididymal protein 4 in the diagnosis of endometrial carcinoma in atypical endometrial hyperplasia patients.","volume":"43","author":"Ding","year":"2016","journal-title":"J Int Obstet Gynecol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.12669\/pjms.334.12755","article-title":"Value of HE4 combined with cancer antigen 125 in the diagnosis of endometrial cancer.","volume":"33","author":"Dong","year":"2017","journal-title":"Pak J Med Sci"},{"key":"R17-20250504","first-page":"73","article-title":"Changes and significance of serum HE4 and CA125 levels in patients with endometrial carcinoma.","volume":"57","author":"Dong","year":"2017","journal-title":"Shandong Med J"},{"key":"R18-20250504","first-page":"49","article-title":"Clinical value of combined detection of serum human epididymal secretory protein E4 and cancer antigen 125 in diagnosis of endometrial carcinoma.","volume":"37","author":"Gao","year":"2016","journal-title":"J Med Forum"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.15296\/ijwhr.2016.07","article-title":"Diagnostic value of novel biomarker human epididymis protein 4 (HE4) in detecting endometrial cancer.","volume":"4","author":"Jafari-Shobeiri","year":"2016","journal-title":"Int J Women\u2019s Health Reprod Sci"},{"key":"R20-20250504","first-page":"47","article-title":"Diagnostic and prognostic value of serum HE4 detection for endometrial carcinoma patients compared with CA 125.","volume":"34","author":"Lin","year":"2014","journal-title":"Curr Immunol"},{"key":"R21-20250504","first-page":"785","article-title":"Diagnostic significance of changes in serum human epididymis epithelial secretory protein 4 and carbohydrate antigen 125 in endometrial carcinoma patients.","volume":"34","author":"Liu","year":"2018","journal-title":"Acta Med Mediterr"},{"key":"R22-20250504","first-page":"1093","article-title":"Value of combined detection of three serum tumor markers in diagnosis of endometrial cancer.","volume":"26","author":"Liu","year":"2020","journal-title":"Int Med Health Guidance News"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","article-title":"Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.","volume":"110","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1007\/s13277-013-0814-z","article-title":"The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.","volume":"34","author":"Omer","year":"2013","journal-title":"Tumour Biol"},{"key":"R25-20250504","first-page":"1903","article-title":"The values of the combined detection of CA125, CA153 and HE4 in diagnosis of endometrial carcinoma.","volume":"16","author":"Qu","year":"2018","journal-title":"Oncol Progress"},{"key":"R26-20250504","first-page":"2","article-title":"Clinical value of combined detection of CA125 and HE4 in diagnosis of endometrial carcinoma.","volume":"37","author":"Sun","year":"2014","journal-title":"Heilongjiang Med Pharm"},{"key":"R27-20250504","first-page":"1","article-title":"Clinical value of serum human epididymis protein E4 combined with cancer antigen 125 in the diagnosis of endometrial cancer.","volume":"25","author":"Tang","year":"2019","journal-title":"Contemp Med"},{"key":"R28-20250504","first-page":"25","article-title":"Clinical value of human epididymis protein 4 and CA125 joint detection in diagnosis of endometrial cancer.","volume":"37","author":"Tao","year":"2016","journal-title":"J Medi Forum"},{"key":"R29-20250504","first-page":"1559","article-title":"Clinical value of combined detection of CA125 and HE4 in diagnosis of endometrial cancer.","volume":"26","author":"Wu","year":"2011","journal-title":"Matern Child Health Care China"},{"key":"R30-20250504","first-page":"220","article-title":"Diagnostic value of HE4 and tumor markers in endometrial cancer.","volume":"19","author":"Yang","year":"2015","journal-title":"J Clin Med Pract"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1515\/cclm-2011-0757","article-title":"Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.","volume":"50","author":"Zanotti","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"R32-20250504","first-page":"125","article-title":"Clinical value of combined detection of serum human epididymal secretory protein E4 and CA125 in the diagnosis of endometrial carcinoma.","volume":"47","author":"Zhang","year":"2012","journal-title":"Chin J Obstet Gynecol"},{"key":"R33-20250504","first-page":"1604","article-title":"Clinical significance on detection of HE4 combined with CA125 in patients\u2019 serum with gynecologic oncology.","volume":"35","author":"Zhang","year":"2016","journal-title":"Genomics Appl Biol"},{"key":"R34-20250504","first-page":"820","article-title":"Differential diagnostic value of combined detection of serum HE4 and CA125 in patients with&nbsp;endometrial carcinoma from benign uterus tumor.","volume":"22","author":"Zhao","year":"2012","journal-title":"China Oncol"},{"key":"R35-20250504","first-page":"1974","article-title":"Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-Analysis.","volume":"20","author":"Chen","year":"2016","journal-title":"Eur Rev Med Pharmacol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djn326","article-title":"Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.","volume":"100","author":"Pepe","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/sim.1099","article-title":"Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data.","volume":"21","author":"Walter","year":"2002","journal-title":"Stat Med"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/cancers13194764","article-title":"HE4 as a biomarker for endometrial cancer.","volume":"13","author":"Behrouzi","year":"2021","journal-title":"Cancers"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cca.2018.11.011","article-title":"Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: a meta-analysis.","volume":"488","author":"Li","year":"2019","journal-title":"Clin Chim Acta"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13048-015-0201-z","article-title":"Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women.","volume":"8","author":"Tian","year":"2015","journal-title":"J Ovarian Res"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/CM9.0000000000000785","article-title":"Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level: a prospective cross-sectional study in healthy Chinese people.","volume":"133","author":"Cheng","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13277-011-0256-4","article-title":"Human epididymis protein 4 reference limits and natural variation in a Nordic reference population.","volume":"33","author":"Bolstad","year":"2012","journal-title":"Tumour Biol"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.2217\/epi-2020-0164","article-title":"DNA methylation markers for endometrial cancer detection in minimally invasive samples: a systematic review.","volume":"12","author":"Den Helder","year":"2020","journal-title":"Epigenomics"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"eaap8793","DOI":"10.1126\/scitranslmed.aap8793","article-title":"Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.","volume":"10","author":"Wang","year":"2018","journal-title":"Sci Transl Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T21:06:53Z","timestamp":1746306413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":44,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034737","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]}}}